INTE:LIGAND SOFTWARE-ENTWICKLUNGS- UND CONSULTING GMBH

INTE:LIGAND SOFTWARE-ENTWICKLUNGS- UND CONSULTING GMBH specializes in the development and licensing of advanced computational chemistry software solutions, with a focus on ligand-based drug discovery and structure-activity relationship modeling. Their core expertise lies in delivering expert-grade molecular modeling tools, including the LIGANDSCOUT platform and integrated KNIME extensions, which enable researchers to perform remote, high-precision virtual screening, pharmacophore mapping, and 3D similarity analysis. The company’s technical differentiation stems from its deep integration of cheminformatics algorithms with workflow automation frameworks, allowing pharmaceutical and translational science teams to accelerate lead identification and optimize compound design without requiring on-premise computational infrastructure. Their solutions are engineered for scalability in multi-user, floating-license environments, supporting collaborative drug discovery workflows in regulated research settings. The contractor has demonstrated direct engagement with the Department of Health and Human Services, specifically supporting the National Center for Advancing Translational Sciences (NCATS) through the renewal of expert software licenses. This indicates a focused relationship centered on enabling computational drug discovery capabilities for federal biomedical research initiatives, likely in support of precision medicine and repurposing efforts. Their primary industry focus is within the software publishers category (NAICS 513210), where they position themselves as a niche provider of specialized cheminformatics software for life sciences research. They serve the pharmaceutical, biotech, and government-funded translational research sectors, offering proprietary tools that bridge computational chemistry and experimental validation pipelines. INTE:LIGAND is structured as a private German entity based in Maria Enzersdorf, with no public government certifications on record. Their market presence is defined by technical specialization rather than broad federal contracting scale, serving a highly targeted segment of the biomedical software ecosystem through direct licensing and expert support models.